Literature DB >> 2053122

Quantitation of Fansimef components (mefloquine + sulfadoxine + pyrimethamine) in human plasma by two high-performance liquid chromatographic methods.

M D Edstein1, I D Lika, T Chongsuphajaisiddhi, A Sabchareon, H K Webster.   

Abstract

Two simple, precise, and selective high-performance liquid chromatographic methods are described for the simultaneous quantitation of mefloquine (MQ) plus pyrimethamine (PYR) or sulfadoxine (SDX) plus its principal metabolite N4-acetylsulfadoxine (N4SDX) in human plasma. After a single-step extraction, MQ plus PYR and SDX plus N4SDX including internal standards were separated using ion-paired and ion-suppression chromatography. Total run times for the assays were less than 12 min. Intraassay and interassay precision of the methods expressed as the coefficients of variation were less than 9% in plasma for the four compounds. The extraction recovery averaged 98% for MQ, 97% for PYR, 96% for SDX, and 81% for N4SDX. Plasma concentrations of the four compounds in a pediatric patient after a single oral dose of Fansimef (MQ + SDX + PYR) were determined to demonstrate the clinical application of the methods.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2053122     DOI: 10.1097/00007691-199103000-00010

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  The influence of body weight on the pharmacokinetics of mefloquine.

Authors:  J A SImpson; L Aarons; R Price; N J White
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

2.  Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.

Authors:  Stéphane Corvaisier; Bruno Charpiat; Cyril Mounier; Martine Wallon; Gilles Leboucher; Mounzer Al Kurdi; Jean-François Chaulet; François Peyron
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

3.  Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients.

Authors:  F O ter Kuile; F Nosten; C Luxemburger; D Kyle; P Teja-Isavatharm; L Phaipun; R Price; T Chongsuphajaisiddhi; N J White
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

4.  Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria.

Authors:  R Price; J A Simpson; P Teja-Isavatharm; M M Than; C Luxemburger; D G Heppner; T Chongsuphajaisiddhi; F Nosten; N J White
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.